Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 1st 3 Qtrs Business Results
February 21, 2005
- 2/3 of Ethical Drugs Designated as "Rx-only Drugs"
February 21, 2005
- Korosho to Demand PIII Data in NDA for Anticancer Agents
February 21, 2005
- Handling of Applications for Add'l Indications of Anticancer Drugs Notified
February 21, 2005
- Add. Indications Approved for 45 Drugs Used Off-label: JAPIC Seminar
February 21, 2005
- REGULATORY NEWS IN BRIEF
February 21, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 21, 2005
- MONITOR
February 21, 2005
- Aiming at Acquiring "Absolute No.1" in Diagnostic Market: Mr Ogawa of RDKK
February 21, 2005
- The Society of Japanese Pharmacopoeia Seminar
February 21, 2005
- OTC NEWS IN BRIEF
February 21, 2005
- Kringle, Galeni Make Research Evaluation Accord
February 21, 2005
- FPMAJ's GL on Handling of Personal Information Announced
February 21, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 21, 2005
- JPEC to Start GMP Compliance Certification for Pharm. Excipients
February 21, 2005
- DIAGNOSTIC NEWS IN BRIEF
February 21, 2005
- Alfresa to Train MSs to Help Boost Profits, Cut Costs
February 21, 2005
- 1st 3 Qtrs Business Results
February 21, 2005
- 1st 3Qtrs Business Results
February 14, 2005
- Drug Administration Is at Crossroads: New GAD Director
February 14, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…